Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

Rebecca J. Lee , Oskar Wysocki , Cong Zhou , Rohan Shotton , Ann Tivey , Louise Lever , Joshua Woodcock , Laurence Albiges (1, 2) , Angelos Angelakas , Dirk Arnold (3) , Theingi Aung , Kathryn Banfill , Mark Baxter , Fabrice Barlesi (4, 1) , Arnaud Bayle (5) , Benjamin Besse (1, 6) , Talvinder Bhogal , Hayley Boyce , Fiona Britton , Antonio Calles , Luis Castelo-Branco , Ellen Copson (7) , Adina E. Croitoru , Sourbha S. Dani , Elena Dickens , Leonie Eastlake , Paul Fitzpatrick , Stephanie Foulon (8) , Henrik Frederiksen (9) , Hannah Frost , Sarju Ganatra , Spyridon Gennatas , Andreas Glenthoj (10) , Fabio Gomes (11) , Donna M. Graham , Christina Hague , Kevin Harrington , Michelle Harrison , Laura Horsley , Richard Hoskins , Prerana Huddar , Zoe Hudson , Lasse H. Jakobsen , Nalinie Joharatnam-Hogan , Sam Khan , Umair T. Khan , Khurum Khan , Christophe Massard (12) , Alec Maynard , Hayley Mckenzie , Olivier Michielin (13) , Anne C. Mosenthal , Berta Obispo , Rushin Patel , George Pentheroudakis (14) , Solange Peters (13) , Kimberly Rieger-Christ , Timothy Robinson , Jacobo Rogado , Emanuela Romano (15) , Michael Rowe , Marina Sekacheva , Roseleen Sheehan , Julie Stevenson , Alexander Stockdale , Anne Thomas , Lance Turtle (16) , David Vinal , Jamie Weaver , Sophie Williams , Caroline Wilson , Carlo Palmieri (16) , Donal Landers , Timothy Cooksley , Caroline Dive (17) , Andre Freitas (18) , Anne C. Armstrong (19)

1 IGR - Institut Gustave Roussy
2 Oncologie gynécologique
3 PTB - Physikalisch-Technische Bundesanstalt [Braunschweig]
4 CRCM - Centre de Recherche en Cancérologie de Marseille
5 Cancer Research and Personalized Medicine - CARPEM [Paris]
6 Département de médecine oncologique [Gustave Roussy]
7 Genetics
8 CESP - Centre de recherche en épidémiologie et santé des populations
9 Hematology
10 Department of Clinical Microbiology [Rigshospitalet]
11 University of Manchester [Manchester]
12 DITEP - Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy]
13 CHUV - Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne]
14 Department of Medical Oncology
15 U932 - Immunité et cancer
16 University of Liverpool
17 Clinical and Experimental Pharmacology Group
18 UNICAMP - Universidade Estadual de Campinas = University of Campinas
19 Cancer Research UK Department of Medical Oncology

PURPOSE Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, and increased monitoring for early intervention are critical. We sought to identify features of COVID-19 disease in patients with cancer predicting severe disease and build a decision support online tool, COVID-19 Risk in Oncology Evaluation Tool (CORONET). METHODS Patients with active cancer (stage I-IV) and laboratory-confirmed COVID-19 disease presenting to hospitals worldwide were included. Discharge (within 24 hours), admission (>= 24 hours inpatient), oxygen (O-2) requirement, and death were combined in a 0-3 point severity scale. Association of features with outcomes were investigated using Lasso regression and Random Forest combined with Shapley Additive Explanations. The CORONET model was then examined in the entire cohort to build an online CORONET decision support tool. Admission and severe disease thresholds were established through pragmatically defined cost functions. Finally, the CORONET model was validated on an external cohort. RESULTS The model development data set comprised 920 patients, with median age 70 (range 5-99) years, 56% males, 44% females, and 81% solid versus 19% hematologic cancers. In derivation, Random Forest demonstrated superior performance over Lasso with lower mean squared error (0.801 v 0.807) and was selected for development. During validation (n = 282 patients), the performance of CORONET varied depending on the country cohort. CORONET cutoffs for admission and mortality of 1.0 and 2.3 were established. The CORONET decision support tool recommended admission for 95% of patients eventually requiring oxygen and 97% of those who died (94% and 98% in validation, respectively). The specificity for mortality prediction was 92% and 83% in derivation and validation, respectively. Shapley Additive Explanations revealed that National Early Warning Score 2, C-reactive protein, and albumin were the most important features contributing to COVID-19 severity prediction in patients with cancer at time of hospital presentation. CONCLUSION CORONET, a decision support tool validated in health care systems worldwide, can aid admission decisions and predict COVID-19 severity in patients with cancer. (C) 2022 by American Society of Clinical Oncology

Domaines: Sciences du Vivant [q-bio]

Rebecca J. Lee, Oskar Wysocki, Cong Zhou, Rohan Shotton, Ann Tivey, et al.. Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. JCO Clinical Cancer Informatics, 2022, 6, ⟨10.1200/CCI.21.00177⟩. ⟨hal-04085312⟩